High-sensitivity C-reactive protein and hypertension: combined effects on coronary severity and cardiovascular outcomes

[1]  H. May,et al.  GlycA and hsCRP are independent and additive predictors of future cardiovascular events among patients undergoing angiography: The intermountain heart collaborative study , 2018, American heart journal.

[2]  E. Rimm,et al.  Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank , 2018, European heart journal.

[3]  P. Ridker,et al.  Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy , 2018, Circulation.

[4]  Yuan-Lin Guo,et al.  Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes , 2018, Hypertension.

[5]  W. Cushman,et al.  High‐sensitivity C‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial , 2017, Diabetes, obesity & metabolism.

[6]  P. Libby,et al.  Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial , 2017, The Lancet.

[7]  S. Ishikawa,et al.  High-sensitivity C reactive protein as a predictor of inhospital mortality in patients with cardiovascular disease at an emergency department: a retrospective cohort study , 2017, BMJ Open.

[8]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[9]  Yuan-Lin Guo,et al.  High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease. , 2017, Atherosclerosis.

[10]  Weijian Huang,et al.  Serum Markers of Endothelial Dysfunction and Inflammation Increase in Hypertension with Prediabetes Mellitus. , 2016, Genetic testing and molecular biomarkers.

[11]  Paul M Ridker,et al.  The Present and FutureReview Topic of the WeekA Test in Context: High-Sensitivity C-Reactive Protein , 2016 .

[12]  R. Giugliano,et al.  Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[13]  P. Ridker,et al.  Association Between High-Sensitivity C-Reactive Protein and Total Stroke by Hypertensive Status Among Men , 2015, Journal of the American Heart Association.

[14]  Michael J Blaha,et al.  High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? , 2013, Journal of the American College of Cardiology.

[15]  D. Goff,et al.  Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. , 2012, JAMA.

[16]  A. Hofman,et al.  Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification , 2012, Annals of Internal Medicine.

[17]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[18]  E. Stamatakis,et al.  Physical activity and risk of cardiovascular disease events: inflammatory and metabolic mechanisms. , 2009, Medicine and science in sports and exercise.

[19]  G. Niccoli,et al.  Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. , 2009, Clinical chemistry.

[20]  Anders Larsson,et al.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.

[21]  M. Pfeffer,et al.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[22]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[23]  A. Denktas,et al.  Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. , 2006, European heart journal.

[24]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[25]  L. Niskanen,et al.  Inflammation, Abdominal Obesity, and Smoking as Predictors of Hypertension , 2004, Hypertension.

[26]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[27]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[28]  S. Blankenberg,et al.  Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. , 2002, The American journal of cardiology.

[29]  G. Hansson,et al.  The Role of Adaptive Immunity in Atherosclerosis , 2000, Annals of the New York Academy of Sciences.

[30]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[31]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[32]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[33]  G. Gensini,et al.  A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.